Loss of p38δ expression promotes oesophageal squamous cell carcinoma proliferation, migration and anchorage-independent growth

International Journal of Oncology

Volumn 43, Issue 2, 2013, Pages 405-415

  O'Callaghan, Carol ^a   Fanning, Liam J ^a   Houston, Aileen ^a   Barry, Orla Patricia ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Anchorage independent growth; Migration; Oesophageal cancer; p38 mitogen activated protein kinase; Proliferation

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 13;

ADULT; AGED; ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER CELL CULTURE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MAP KINASE KINASE 6; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 11; MITOGEN-ACTIVATED PROTEIN KINASE 12; MITOGEN-ACTIVATED PROTEIN KINASE 13; MITOGEN-ACTIVATED PROTEIN KINASE 14; PROTEIN ISOFORMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84879629285     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.1968     Document Type: Article

References (45)

1. Kayani B, Zacharakis E, Ahmed K and Hanna GB: Lymph node metastases and prognosis in oesophageal carcinoma - a systematic review. Eur J Surg Oncol 37: 747-753, 2011.
2. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003. (Pubitemid 37485141)
3. Almhanna K and Strosberg JR: Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 18: 5679-5687, 2012.
4. Thallinger CM, Kiesewetter B, Raderer M and Hejna M: Pre-and postoperative treatment modalities for esophageal squamous cell carcinoma. Anticancer Res 32: 4609-4627, 2012.
5. Klein CA and Stoecklein NH: Lessons from an aggressive cancer: evolutionary dynamics in esophageal cancer. Cancer Res 69: 5285-5288, 2009.
6. Bird-Lieberman EL and Fitzgerald RC: Early diagnosis of oesophageal cancer. Br J Cancer 101: 1-6, 2009.
7. Sanz V, Arozarena I and Crespo P: Distinct carboxy-termini confer divergent characteristics to the mitogen-activated protein kinase p38α and its splice isoform Mxi2. FEBS Lett 474: 169-174, 2000. (Pubitemid 30330828)
8. Raman M, Chen W and Cobb MH: Differential regulation and properties of mapks. Oncogene 26: 3100-3112, 2007. (Pubitemid 46763006)
9. Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H and Wagner EF: P38alpha suppresses normal and cancer cell proliferation by antagonizing the jnk-c-jun pathway. Nat Genet 39: 741-749, 2007. (Pubitemid 46848584)
10. Ono K and Han J: The p38 signal transduction pathway: activation and function. Cell Signal 12: 1-13, 2000. (Pubitemid 30017963)
11. Zarubin T and Han J: Activation and signaling of the p38 MAP kinase pathway. Cell Res 15: 11-18, 2005. (Pubitemid 41653958)
12. Kyriakis JM and Ayruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 92: 689-737, 2012.
13. Cuenda A and Rousseau S: p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375, 2007. (Pubitemid 47125981)
14. Eyers PA, Craxton M, Morrice N, Cohen P and Goedert M: Conversion of SB 203580-insensitive MAP kinase family members to drug-sensitive forms by a single amino-acid substitution. Chem Biol 5: 321-328, 1998. (Pubitemid 28309985)
15. Yamana H, Kakegawa T, Tanaka T, Higaki K, Fujii T and Tou U: Experimental studies on immunotargeting therapy for esophageal carcinoma. Gan To Kagaku Ryoho 21: 755-760, 1994. (Pubitemid 24183846)
16. Tsukahara T, Nabeta Y, Kawaguchi S, Ikeda H, Sato Y, Shimozawa K, Ida K, Asanuma H, Hirohashi Y, Torigoe T, Hiraga H, Nagoya S, Wada T, Yamashita T and Sato N: Identification of human autologous cytotoxic T-lymphcyte-defined osteosarcoma gene that encodes a transcriptional regulator, papillomavirus binding factor. Cancer Res 64: 5442-5448, 2004. (Pubitemid 39006567)
17. Nakao M, Yamann H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S, Kakegawa T and Hoir K: HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamous cell carcinoma. Cancer Res 55: 4248-4252, 1995.
18. Barry OP, Mullan B, Sheehan D, Kazanietz MG, Shanahan F, Collins JK and O'Sullivan GC: Constitutive ERK1/2 activation in esophagogastric rib bone marrow micrometastatic cells is MEK-independent. J Biol Chem 276: 15537-15546, 2001.
19. Pramanik R, Qi X, Borowicz S, Choubey D, Schultz RM, Han J and Chen G: p38 isoforms have opposite effects on AP-1-dependent transcription through regulation of c-Jun. The determinant roles of the isoforms in the p38 MAPK signal specificity. J Biol Chem 278: 4831-4839, 2003. (Pubitemid 36800988)
20. Zheng C, Xiang J, Hunter T and Lin A: The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun Kinase that stimulates c-Jun transcription activity. J Biol Chem 274: 28966-28971, 1999.
21. O'Sullivan GC, Tangney M, Casey G, Ambrose M, Houston A and Barry OP: Modulation of p21-activated kinase 1 alters the behavior of renal cell carcinoma. Int J Cancer 121: 1930-1940, 2007. (Pubitemid 47463155)
22. Chen L, Zhang JJ and Huang XY: cAMP inhibits cell migration by interfering with Rac-induced lamellipodium formation. J Biol Chem 283: 13799-13805, 2008.
23. Adhikary G, Chew YC, Reece EA and Eckert RL: PKC-delta and -eta, MEKK-1, MEK-6, MEK-3 and p38-delta are essential mediators of the response of normal human epidermal keratinocytes to differentiating agents. J Invest Dermatol 130: 2017-2030, 2010.
24. Cargnello M and Roux P: Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75: 50-83, 2011.
25. Wagner EF and Nebreda ÁR: Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549, 2009.
26. Ambrose M, Ryan A, O'Sullivan GC, Dunne C and Barry OP: Induction of apoptosis in renal cell carcinoma by reactive oxygen species: involvement of extracellular signal-regulated kinase 1/2, p38delta/gamma, cyclooxygenase-2 down-regulation and translocation of apoptosis-inducing factor. Mol Pharmacol 69: 1879-1890, 2006. (Pubitemid 43894304)
27. Remy G, Risco AM, Iñesta-Vaquera FA, González-Terán B, Sabio G, Davis RJ and Cuenda A: Differential activation of p38MAPK isoforms by MKK6 and MKK3. Cell Signal 22: 660-667, 2010.
28. Reid TD, Sanyaolu LN, Chan D, Williams GT and Lewis WG: Relative prognostic value of TNM7 vs TNM6 in staging oesophageal cancer. Br J Cancer 105: 842-846, 2011.
29. Junttila MR, Ala-aho R, Jokilehto T, Peltonen J, Kallajoki M, Grenman R, Jaakkola P, Westermarck J and Kähäri V-M: p38α and p38δ mitogen-activated protein kinase isoforms regulate invasion and growth of head and neck squamous carcinoma cells. Oncogene 26: 5267-5279, 2007.
30. Efimova T, Broome A-M and Eckert RL: Protein kinase Cδ regulates keratinocyte death and survival by regulating activity and subcellular localization of a p38δ-extracellular signal-regulated kinase 1/2 complex. Mol Cell Biol 24: 8167-8183, 2004. (Pubitemid 39167465)
31. Efimova T, Broome AM and Eckert RL: A regulatory role for p38δ MAPK in keratinocyte differentiation. Evidence for p38δ-ERK1/2 complex formation. J Biol Chem 278: 34277-34285, 2003. (Pubitemid 37553271)
32. Li Q, Zhang N, Zhang D,Wang Y, Lin T, Wang Y, Zhou H, Ye Z, Zhang F, Lin S-C and Han J: Determinants that control the distinct subcellular localization of p38α-PRAK and p38β-PRAK complexes. J Biol Chem 283: 11014-11023, 2008.
33. Fan L, Yang X, Du J, Marshall M, Blanchard K and Ye X: A novel role of p38α MAPK in mitotic progression independent of its kinase activity. Cell Cycle 4: 1616-1624, 2005.
34. Tang J, Qi X, Mercola D, Han J and Chen G: Essential role of p38γ in K-Ras transformation independent of phosphorylation. J Biol Chem 280: 23910-23917, 2005. (Pubitemid 40884879)
35. Del Barco Barrantes I and Nebreda AR: Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 40: 79-84, 2012.
36. Izzo JG, Luthra R, Sims-Mourtada J, Chao KSC, Lee JH, Wu T-T, Correa AM, Luthra M, Aggarwal B, Hung M-C and Ajani JA: Emerging molecular targets in esophageal cancers. Gastrointest Cancer Res 1: S3-S6, 2007.
37. Bulavin DV and Fornace AJ: p38 MAP kinases's emerging role as a tumour suppressor. Adv Cancer Res 92: 95-118, 2004. (Pubitemid 39458114)
38. Hui L, Bakiri L, Stepniak E and Wagber EF: p38α a supressor of cell proliferation and tumorigenesis. Cell Cycle 6: 2429-2433, 2007. (Pubitemid 350058657)
39. Ventura JJ, Tenbaum S, Perdiguero E, Huth M, Guerra C, Barbacid M, Pasparakis M and Nebreda AR: p38α MAP kinase is essential in lung stem and progenitor cell proliferation and differentiation. Nat Genet 39: 750-758, 2007. (Pubitemid 46848588)
40. Schindler EM, Hindes A, Gribben EL, Burns CJ, Yin Y, Lin M-H, Owen RJ, Longmore GD, Kissling GE, Arthur JSC and Efimova T: p38δ mitogen-activated protein kinase is essential for skin tumor development in mice. Cancer Res 69: 4648-4655, 2009.
41. Cerezo-Guisado MI, Del Reino P, Remy G, Kuma Y, Arthur JSC, Gallego-Ortega D and Cuenda A: Evidence of p38γ and p38δ involvement in cell transformation processes. Carcinogenesis 32: 1093-1099, 2011.
42. Sundaramurthy P, Gakkhar S and Sowdhamini R: Analysis of the impact of ERK5, JNK and p38 kinase cascades on each other: a systems approach. Bioinformation 3: 244-249, 2009.
43. Ambrosino C, Mace G, Galban S, Fritsch C, Vintersten k, Black E, Gorospe M and Nebreda AR: Negative feedback regulation of MKK6 mRNA stability by p38α mitogen-activated protein kinase. Mol Cell Biol 23: 370-381, 2003. (Pubitemid 36008527)
44. Coulthars LR, White DE, Jones DL, McDermott MF and Burchill SA: p38MAPK: stress responses from molecular mechanisms to therapeutics. Trends Mol Med 15: 369-379, 2009.
45. Gaestel M and Kracht M: Peptides as signalling inhibitors for mammalian MAP kinase cascades. Curr Pharm Des 15: 2471-2480, 2009.